The Unitaid-funded ASCENT project aims to help patients succeed in TB treatment using digital adherence technology

Tuberculosis (TB) is still the deadliest infectious disease worldwide, killing over 4.000 people every day. This is unnecessary as TB can be cured with appropriate treatment. A number of barriers however, prevent patients from recovering from this disease, including long and complicated treatment regimens that involve the daily intake of medicines over the course of 6-24 months.

By leveraging today’s smart information and (mobile) communication technologies the ASCENT project (Adherence Support Coalition to End TB) aims to support TB patients with their treatment in a modern and more effective way through the use of digital adherence technologies such as smart pill boxes, medication sleeves and video supported treatment.

By generating evidence, establishing a global market and engaging stakeholders, ASCENT aims to make future scale up possible so that these digital innovations can be available to all TB patients worldwide.

news & Stories

South Africa

ASCENT South-Africa launches in Cape Town


The ASCENT project is collaborating with City Health, and TB HIV Care funded by the Global Fund to implement Digital Adherence Technologies (DATs), to support tuberculosis (TB) patients to successfully complete their treatment in the Western Cape.

Why adherence to treatment is so important

Problem statement:

Missing doses of medication during tuberculosis treatment has serious negative effects
Patients are more likely to stop their TB treatment
Patients can develop resistance to anti TB drugs
Patients are more likely to get TB again

what is Tuberculosis?

Funding & support

Consortium partners

Funding & Support

Consortium partners

more about the ascent project